Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
BioSpace4d
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Truist Financial Sticks to Its Hold Rating for Incyte (INCY)
Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed ...
How greed and profit fueled one failed Alzheimer drug
Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...
Fashion, cigarette stocks lead market up slightly
Wall Street drifted through mixed trading Thursday as rising fashion and cigarette stocks worked against drops for Ford Motor ...
Eli Lilly Stock Rises After Earnings Beat Forecasts
Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...
Inventory issues hobble Lilly sales
Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
devdiscourse8d
Markets Mix As Investors Focus on Earnings and AI Developments
The recent trading session saw the S&P 500 and Nasdaq rise while the Dow fell amid mixed corporate earnings and anticipation of Amazon's results. Notable movements included Nvidia's gain and Honeywell ...
Stock market today: Wall Street finishes mixed as strong fashion, tobacco stocks offset Ford's drop
In stock markets abroad, London’s FTSE 100 jumped 1.2% after the Bank of England cut its main interest rate as it slashed its ...